82 completed, 43 terminated, 9 withdrawn, 8 unknown. 86 Phase 1, 79 Phase 2, 3 Phase 3, 1 Early Phase 1, 1 Phase 4.
Follow Panobinostat: new trials by email Literature Review of Panobinostat trials Research Report on Panobinostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Optimizing Reversal of HIV Latency With Combination Therapy Panobinostat 20 MG Oral Capsule, Pyrimethamine 200mg Oral Tablet, Lenalidomide 25 MG Oral Capsule - Hiv | Phase 1 / Phase 2 | Unknown | Erasmus Medical Center | 49 | 2024-04-01 | 2024-02-05 |
| Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer Alectinib, Cetuximab, Crizotinib - Metastatic Colorectal Cancer | Phase 2 | Recruiting | Oslo University Hospital | 40 | 2022-09-27 | 2023-02-21 |
| Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | Terminated | Abdullah Khan | 1 | 2021-09-27 | 2024-06-06 |
| Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG) Panobinostat 15 MG, Focused Ultrasound with neuro-navigator-controlled sonication - Diffuse Intrinsic Pontine Glioma, Diffuse Pontine and Thalamic Gliomas | Phase 1 | Terminated | Columbia University | 5 | 2021-07-28 | 2025-06-08 |
| Phase I Study of Marizomib + Panobinostat for Children With DIPG Marizomib, Panobinostat - Diffuse Intrinsic Pontine Glioma, Pediatric Brainstem Glioma | Phase 1 | Terminated | Dana-Farber Cancer Institute | 4 | 2020-08-10 | 2024-02-15 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat Farydak - Multiple Myeloma | Completed | pharmaand GmbH | 248 | 2019-11-04 | 2023-06-15 | |
| A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas Panobinostat, Everolimus - Glioma, Diffuse Intrinsic Pontine Glioma | Phase 2 | Withdrawn | University of Michigan Rogel Cancer Center | 2019-10-01 | 2019-08-19 | |
| PDR001 + Panobinostat for Melanoma and NSCLC PDR001, Panobinostat - Melanoma, Non Small Cell Lung Cancer | Phase 1 | Withdrawn | Muhammad Furqan | 2019-09-01 | 2019-10-04 | |
| A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT Panobinostat - Rhabdoid Tumor, Atypical Teratoid/Rhabdoid Tumor | Phase 2 | Terminated | Australian & New Zealand Children's Haematology/Oncology Group | 25 | 2019-01-09 | 2025-02-24 |
| Panobinostat Maintenance After HSCT fo High-risk AML and MDS Panobinostat - Acute Myeloid Leukaemia (AML), Myelodysplastic Syndromes (MDS) | Phase 3 | Terminated | Goethe University | 52 | 2018-07-24 | 2023-02-16 |
| Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Carfilzomib, Chemosensitivity Assay, Dexamethasone - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Terminated | University of Washington | 9 | 2018-02-08 | 2022-05-09 |
| Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat Panobinostat, Carfilzomib, Lenalidomide - Multiple Myeloma | Phase 1 / Phase 2 | Withdrawn | H. Lee Moffitt Cancer Center and Research Institute | 2017-06-01 | 2017-04-25 | |
| Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma Palifermin, Panobinostat, Gemcitabine - Lymphoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2017-06-01 | 2017-04-21 | |
| Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma panobinostat (capsules), carfilzomib (infusion), dexamethasone (tablets) - Multiple Myeloma | Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2016-12-01 | 2016-11-08 | |
| Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma Dexamethasone, Panobinostat, Liposomal vincristine - Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's | Phase 2 | Terminated | St. Jude Children's Research Hospital | 3 | 2016-11-23 | 2019-04-03 |
| A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat PDR001, LCL161, Everolimus - Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma | Phase 1 | Completed | Novartis Pharmaceuticals | 298 | 2016-10-14 | 2023-01-11 |
| Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma LBH589 - Glioma | Phase 1 | Completed | Pediatric Brain Tumor Consortium | 53 | 2016-06-28 | 2024-04-25 |
| A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM) Revlimid, Velcade, dexamethasone - Multiple Myeloma | Phase 2 | Terminated | Novartis Pharmaceuticals | 6 | 2016-06-14 | 2018-07-24 |
| Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT) Panobinostat - Multiple Myeloma | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 30 | 2016-06-10 | 2022-11-01 |
Showing 20 of 147. Sign in to see all of them.
Multiple Myeloma (32) · Leukemia, Myeloid, Acute (14) · Recurrence (14) · Hodgkin Disease (12) · Lymphoma (11) · Myelodysplastic Syndromes (10) · Neoplasms (10) · Breast Neoplasms (9) · Lymphoma, Large B-Cell, Diffuse (8) · Lymphoma, Non-Hodgkin (8) · Carcinoma, Non-Small-Cell Lung (7) · Leukemia (7) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (7) · Prostatic Neoplasms (7) · Lymphoma, T-Cell, Cutaneous (6)
Novartis Pharmaceuticals (43) · H. Lee Moffitt Cancer Center and Research Institute (7) · M.D. Anderson Cancer Center (7) · SCRI Development Innovations, LLC (7) · Dana-Farber Cancer Institute (4) · City of Hope Medical Center (3) · Emory University (2) · Massachusetts General Hospital (2) · Mayo Clinic (2) · Roswell Park Cancer Institute (2) · Southern Europe New Drug Organization (2) · St. Jude Children's Research Hospital (2) · Translational Research in Oncology (2) · University of California, San Francisco (2) · University of Wisconsin, Madison (2)
United States (112) · Germany (25) · Italy (15) · Australia (13) · France (13) · Spain (13) · Canada (12) · Belgium (11) · Netherlands (11) · United Kingdom (10) · Japan (7) · South Korea (7) · Sweden (7) · Switzerland (7) · Israel (5)
Leslie Popplewell, MD (2) · Yasuhiro Oki, MD (2) · Abdullah Kutlar, MD (1) · Abdullah M Khan, MBBS, MSc (1) · Ahmad A Tarhini, MD (1) · Ahmad Tarhini, MD (1) · Ajai Chari, MD (1) · Alessandro Levis, MD (1) · Anand Jillella, MD (1) · Andrew Cowan (1) · Anna Ferrari, MD (1) · Anne Traynor, M.D. (1) · Anne W. Beaven, MD (1) · Arkadiusz Dudek, MD (1)
PMID 25939707, PMID 39863139, PMID 21706316, PMID 21964801, PMID 21984064, PMID 22072492, PMID 22981498, PMID 23287861, PMID 23701016, PMID 23822537, PMID 23922114, PMID 23950178, PMID 24135804, PMID 25062770, PMID 25242045, PMID 25253045, PMID 25377157, PMID 25572329, PMID 25710456, PMID 26160880, PMID 26423811, PMID 26631116, PMID 26688485, PMID 26696749, PMID 26774555, PMID 26903311, PMID 27166360, PMID 27245095, PMID 27261467, PMID 27677481, PMID 27740633, PMID 27751707, PMID 27843120, PMID 28546581, PMID 28622959, PMID 28905323, PMID 29296798, PMID 30501870, PMID 30610196, PMID 30830886, PMID 31541945, PMID 31654285, PMID 31778911, PMID 32338562, PMID 33279887, PMID 33301738, PMID 33421178, PMID 34242388, PMID 34482353, PMID 37189240
2009 (8), 2008 (3), P30CA033572 (3), 2005 (1), 2014 (1), 2015 (1), 5UM1CA081457 (1), P30CA015083 (1), P30CA015704 (1), P30CA016672 (1), P30CA043703 (1)